Liraglutide

Victoza · Saxenda

GLP-1 Receptor Agonist GLP-1 Weight Loss SubQ FDA/EMA Label

Half-life

13 hr

Time to Peak

10 hr

Steady State

~3 days

Bioavailability

55%

Dose Range

0.6–3 mg

Frequency

Daily

Overview

Once-daily injectable GLP-1 receptor agonist for type 2 diabetes (Victoza) and chronic weight management (Saxenda). First long-acting GLP-1 RA widely adopted for weight loss.

Mechanism of Action

GLP-1 receptor agonist with 97% homology to native GLP-1. Fatty acid side chain enables albumin binding for extended duration vs native GLP-1.

Dosing Information

Route	Dose Range	Half-life	Tmax	Frequency
Subcutaneous (SubQ)	0.6–3 mg	13 hr	10 hr	Daily

Storage & Handling

2-8C — Refrigerate before first use. After first use: room temp (15-30C) or refrigerated for up to 30 days. Do not freeze.

Used in Regimens

1 regimen

GLP-1 Switch — Liraglutide → Semaglutide

Transition from liraglutide (Saxenda, daily injection) to semaglutide (Ozempic/Wegovy, weekly injection). Semaglutide produces superior weight loss at equivalent or lower doses and requires only weekly injections vs daily.

Liraglutide — final dose before switch to semaglutide.

glp1

Primary

Data Sources

FDA Label Victoza FDA Prescribing Information
FDA Label Saxenda FDA Prescribing Information

Related Tools

Medication Level Plotter

See blood level curves for this compound

Dose Calculator

Calculate reconstitution and draw volumes

Split Dose Calculator

Divide your weekly dose into multiple injections

Track Liraglutide with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.